Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $50.34 and last traded at $49.33, with a volume of 365422 shares changing hands. The stock had previously closed at $48.24.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on RAPP shares. UBS Group reissued a "strong-buy" rating on shares of Rapport Therapeutics in a research report on Monday, August 17th. Wall Street Zen downgraded shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Raymond James Financial reiterated a "strong-buy" rating and issued a $75.00 price objective on shares of Rapport Therapeutics in a report on Monday, August 17th. Truist Financial started coverage on shares of Rapport Therapeutics in a research report on Monday, May 18th. They issued a "buy" rating and a $56.00 price objective for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $62.86.
Get Our Latest Analysis on Rapport Therapeutics
Rapport Therapeutics Trading Up 2.3%
The stock has a market capitalization of $2.37 billion, a P/E ratio of -16.23 and a beta of 0.97. The stock's 50 day simple moving average is $42.34 and its 200 day simple moving average is $36.26.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, sell-side analysts expect that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO Abraham Ceesay sold 28,958 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the sale, the chief executive officer directly owned 486,108 shares of the company's stock, valued at $23,338,045.08. The trade was a 5.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 54,113 shares of company stock valued at $2,546,243 in the last three months. 12.48% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Johnson & Johnson bought a new position in Rapport Therapeutics during the second quarter worth $74,360,823,000. Swedbank AB bought a new stake in Rapport Therapeutics during the fourth quarter valued at $3,434,000. Walleye Capital LLC bought a new stake in Rapport Therapeutics during the second quarter valued at $4,257,000. Dimensional Fund Advisors LP raised its holdings in shares of Rapport Therapeutics by 168.9% during the first quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company's stock worth $7,025,000 after purchasing an additional 141,011 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock worth $91,077,000 after purchasing an additional 579,903 shares during the period.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
